Division of Infectious Diseases

David L. Wyles, M.D.

David L. Wyles, M.D.
Associate Professor of Medicine

UCSD, 9500 Gilman Drive
Mail Code 0711
La Jolla, CA 92093-0711

Telephone: (858)822-1779
Fax: (858) 822-5362
Email: dwyles@ucsd.edu


David L. Wyles, MD is an Associate Professor of Medicine in the Department of Medicine, Division of Infectious Diseases at the University of California, San Diego. Dr. Wyles graduated from the Northwestern University Feinberg School of Medicine in 1998. He completed his Internal Medicine residency and Infectious Diseases fellowship at the University of Colorado Health Sciences Center. In 2005 he moved from the University of Colorado to UCSD. Dr. Wyles' research interests include the laboratory evaluation of new antiviral therapies for Hepatitis C virus (HCV), drug resistance to HCV antivirals, and HCV viral fitness. Clinically Dr. Wyles is involved in trials of novel therapies for chronic HCV and the care of patients co-infected with HIV-1 and HCV.

Selected Publications

Carnevali M, Parsons J, Wyles DL, Hermann T. A Modular Approach to Synthetic RNA Binders of the Hepatitis C Virus Internal Ribosome Entry Site. Chembiochem 2010; 11(10):1364-7.

Wyles DL. Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection. Top HIV Med 2010; 18(4): 132-6.

Taylor LE, Holubar M, Kunling W, Bosch R, Wyles DL, Davis JA, Mayer KH, Sherman KE, Tashima KT. Incident Hepatitis C virus infection among U.S. HIV-infected men enrolled in clinical trials. Clin Infect Dis 2011; 52(6): 812-8.

Valiaeva N,Wyles DL, Schooley RT, Hwu JB, Beadle JR, Prichard MN, Hostetler KY. Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl] nucleoside alkoxyalkyl esters: Inhibitors of hepatitis C virus and HIV-1 replication. Bioorg Med Chem 2011; 19(15): 4616-25.

Cachay ER, Wyles DL, Goicoechea M, Torriani FJ, Ballard C, Colwell B, Gish RG, Mathews WC. Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. AIDS Res Ther. 2011; 8: 29.

Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley RT, Wyles DL. Evaluation of ITX 5061, a Scavenger Receptor B1 (SR-B1) Antagonist: Resistance selection and activity in combination with other Hepatitis C virus (HCV) antivirals. J Infect Dis. 2012 Feb; 205(4): 656-62.

Dibrov SM, Ding K, Brunn ND, Parker MA, Bergdahl BM,Wyles DL, Hermann T. Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitches. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5223-8. Epub 2012 Mar 19.

Wegzyn CM and Wyles DL. Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). Curr Opin Pharmacol. 2012; 12(5):556-61.

Wyles DL. Hepatitis C virus drug resistance: implications for clinical management. Infect Dis Clin North Am. 2012 Dec; 26(4):967-78.

Wyles DL. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med. 2012 Oct-Nov;20(4):139-45.

Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013 Mar;207 Suppl 1:S33-9.

Cachay ER, Hill L, Ballard C, Colwell B, Torriani F, Wyles D, Mathews WC. Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model. AIDS Res Ther. 2013 Mar 28;10(1):9. doi: 10.1186/1742-6405-10-9.

Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. N Engl J Med. 2013 May 16;368(20):1878-87.